This site is intended for healthcare professionals
News

Phase III ASCENT study of Trodelvy met its primary endpoint of progression-free survival for triple negative breast cancer.- Immunomedics Inc.

Read time: 1 mins
Last updated:13th Jul 2020
Published:12th Jul 2020
Condition: Breast Cancer Triple Neg
Type: drug
Register free for full access to medthority.com